Business Description
Helix BioPharma Corp
NAICS : 325410
SIC : 3741
ISIN : CA4229101098
Total Employee Number:
7Description
Helix BioPharma Corp is a clinical-stage biopharmaceutical company developing therapies in immune-oncology focused on cancer prevention and treatment. The Company is developing a proprietary platform of bio-conjugates targeting hard-to-treat solid tumors over-expressing CEACAM6, including Tumor Defense Breaker, L-DOS47, and three CEACAM6-specific antibody-drug conjugates. Its pre-IND candidates include LEUMUNA, an oral immune checkpoint modulator for hematological malignancies, and GEMCEDA, an oral prodrug of gemcitabine for solid tumors.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 7.92 | |||||
Equity-to-Asset | 0.69 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.11 | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 24.8 | |||||
3-Year EPS without NRI Growth Rate | 23.9 | |||||
3-Year FCF Growth Rate | 31.9 | |||||
3-Year Book Growth Rate | 185.8 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
14-Day RSI | 0.15 | |||||
3-1 Month Momentum % | -1.16 | |||||
6-1 Month Momentum % | -1.37 | |||||
12-1 Month Momentum % | 185 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.45 | |||||
Quick Ratio | 0.45 | |||||
Cash Ratio | 0.42 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -29.2 | |||||
Shareholder Yield % | -1.51 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -27.55 | |||||
ROA % | -21.09 | |||||
ROIC % | -20.71 | |||||
3-Year ROIIC % | 3.96 | |||||
ROC (Joel Greenblatt) % | -109733.33 | |||||
ROCE % | -27.29 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 6.93 | |||||
EV-to-EBIT | -30.1 | |||||
EV-to-EBITDA | -30.14 | |||||
EV-to-FCF | -30.9 | |||||
Earnings Yield (Greenblatt) % | -3.32 | |||||
FCF Yield % | -3.16 |
GF Valueâ„¢
Helix BioPharma Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Helix BioPharma Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| 0.2:1 Stock Split | 2024-08-16 | 0.78 (+0.00%) |
Show
Entries
Guru Commentaries on OTCPK:HBPCF
No articles.
Press Release
Articles on Helix BioPharma Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers